List of Excipients in Branded Drug METHYLPHENIDATE HCL

« Back to Dashboard

Generic Drugs Containing METHYLPHENIDATE HCL

Company	Ingredient	NDC	Excipient
Patrin Pharma Inc	methylphenidate hcl	39328-054	GLYCERIN
Patrin Pharma Inc	methylphenidate hcl	39328-054	GRAPE
Patrin Pharma Inc	methylphenidate hcl	39328-054	PHOSPHORIC ACID
Patrin Pharma Inc	methylphenidate hcl	39328-054	POLYETHYLENE GLYCOL 1450

What are the Most Frequently-Used Excipients in METHYLPHENIDATE HCL?

# Of NDCs	Excipient
1	GLYCERIN
1	GRAPE
1	PHOSPHORIC ACID
1	POLYETHYLENE GLYCOL 1450

Methylphenidate HCl Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: September 5, 2026

Methylphenidate hydrochloride is a mature controlled substance with limited opportunity in conventional immediate-release tablets but substantial formulation value in extended-release, liquid, orally disintegrating, chewable, transdermal, and abuse-deterrent products. The strongest commercial positions depend on excipient systems that control release, improve palatability, support pediatric dosing, reduce manipulation, or enable differentiated regulatory claims.

Key commercial platforms include osmotic controlled-release tablets, multiparticulate capsules, ion-exchange or polymeric suspensions, chewable tablets, orally disintegrating tablets, and transdermal delivery. New entrants face less active-ingredient risk than formulation, manufacturing, regulatory, and controlled-substance compliance risk.

What is methylphenidate HCl and where is it used?

Methylphenidate hydrochloride is a central nervous system stimulant approved primarily for attention deficit hyperactivity disorder and narcolepsy. It is available as racemic methylphenidate HCl and as dexmethylphenidate HCl, the d-enantiomer marketed in products such as Focalin and Focalin XR.

FDA-approved methylphenidate products include:

Product	Sponsor or manufacturer	Dosage form	Release platform
Ritalin	Novartis, historically	Immediate-release tablet, oral solution	Conventional release
Ritalin LA	Novartis, historically	Capsule	Biphasic bead system
Concerta	Janssen, now marketed by multiple parties	Extended-release tablet	OROS osmotic system
Quillivant XR	Tris Pharma	Extended-release oral suspension	Ion-pairing and polymeric release system
QuilliChew ER	Tris Pharma	Extended-release chewable tablet	Controlled-release matrix
Aptensio XR	Rhodes Pharmaceuticals	Extended-release capsule	Multiparticulate bead system
Jornay PM	Ironshore Pharmaceuticals	Extended-release capsule	Delayed-release and extended-release beads
Cotempla XR-ODT	Neos Therapeutics, acquired by Tris Pharma	Extended-release orally disintegrating tablet	Microparticle and polymeric system
Daytrana	Noven Pharmaceuticals	Transdermal patch	Adhesive matrix delivery
Relexxii	Tris Pharma	Extended-release tablet	OROS-type technology

The commercial distinction is not the methylphenidate molecule. It is the delivery profile, administration flexibility, abuse liability, tolerability, and dosing convenience.

What excipients are used in methylphenidate HCl products?

Excipient selection depends on the dosage form and the target pharmacokinetic profile. Public FDA labeling identifies broad excipient classes, although proprietary processing conditions and functional grades are often not fully disclosed.

Immediate-release tablets

Immediate-release methylphenidate tablets generally use standard direct-compression or wet-granulation systems. Relevant excipient functions include:

• Fillers and diluents such as lactose, microcrystalline cellulose, or dibasic calcium phosphate
• Binders such as povidone or hypromellose
• Disintegrants such as crospovidone, croscarmellose sodium, or sodium starch glycolate
• Lubricants such as magnesium stearate or stearic acid
• Film-coating polymers, plasticizers, pigments, and opacifiers
• Flavoring agents for chewable or dispersible formats

The opportunity in this segment is primarily cost reduction, supply security, taste improvement, and conversion to pediatric-friendly dosage forms. Generic competition limits the value of new excipient combinations unless they support a differentiated label or a 505(b)(2) product.

Extended-release tablets

Extended-release methylphenidate tablets require excipients that produce reproducible release over approximately 8 to 12 hours. Hydrophilic matrix polymers, osmotic membranes, pore-forming agents, and mechanical barriers are important.

Concerta uses an osmotic delivery architecture. The tablet includes a drug-containing core, an osmotic layer, a semipermeable membrane, and a laser-drilled orifice. Excipients such as polyethylene oxide, sodium chloride, hypromellose, cellulose derivatives, and membrane coatings can influence hydration, osmotic pressure, tablet integrity, and delivery rate. The OROS design is more difficult to replicate than a conventional hydrophilic matrix because performance depends on geometry, coating thickness, drilling, and manufacturing controls.

Commercial opportunities include:

• Lower-cost osmotic tablets
• Extended-release tablets with less food-effect sensitivity
• Improved dose proportionality
• More robust release after crushing or partial manipulation
• Tablet sizes suitable for pediatric use
• Formulations with reduced gastrointestinal variability

Modified-release capsules and multiparticulates

Ritalin LA, Aptensio XR, and Jornay PM use bead or multiparticulate technologies. These systems can combine immediate-release and delayed-release populations in one capsule.

Typical excipient functions include:

• Sugar spheres or microcrystalline cellulose starter cores
• Drug-layering binders
• Ethylcellulose or acrylic polymers for sustained release
• Enteric polymers such as methacrylic acid copolymers for delayed release
• Anti-tacking agents such as talc or colloidal silicon dioxide
• Plasticizers such as triethyl citrate
• Capsule-shell materials and colorants

Multiparticulates provide several commercial advantages. They can be administered by sprinkling on soft food, support multiple release pulses, and reduce dependence on a single monolithic tablet. The main technical risks are dose uniformity, bead attrition, alcohol effects, food effects, and release changes after opening the capsule.

Jornay PM is commercially differentiated by evening dosing with delayed overnight release followed by daytime exposure. An excipient system that reliably suppresses early release in the stomach and initiates release after a defined lag time has potential in sleep-related dosing and other chronotherapy applications.

What formulations of methylphenidate HCl have the strongest commercial potential?

Extended-release oral suspension

Quillivant XR demonstrates the commercial value of a liquid product for children who cannot swallow tablets or capsules. A suspension must maintain chemical stability, uniform redispersion, acceptable viscosity, palatability, and dose accuracy over the in-use period.

Potential excipient platforms include:

• Ion-exchange resins
• Polymer-coated drug particles
• Suspending agents such as xanthan gum, microcrystalline cellulose, or carboxymethylcellulose
• Wetting agents and surfactants
• Buffer systems
• Preservatives
• Sweeteners and flavor systems
• Antifoaming agents

A strong liquid platform should minimize settling, reduce caking, limit dose variability between shakes, and maintain release performance after storage and repeated opening. Taste masking is a major value driver because methylphenidate has a bitter taste and pediatric adherence is sensitive to palatability.

Extended-release chewable tablets

QuilliChew ER addresses children who cannot swallow conventional dosage forms but can chew tablets. The excipient strategy must balance chewability, mechanical strength, controlled release, taste masking, and dose uniformity.

Commercially attractive technologies include coated drug particles embedded in a chewable matrix, lipid-based taste-masking systems, ion-exchange resins, and compressed multiparticulates. The formulation should avoid excessive hardness, grittiness, aftertaste, and rapid release after chewing.

Orally disintegrating tablets

Cotempla XR-ODT uses an orally disintegrating extended-release platform. This product category requires rapid oral disintegration without losing the intended controlled-release profile.

Useful excipient systems include:

• Mannitol or other water-soluble fillers
• Crospovidone or low-substituted hydroxypropyl cellulose
• Taste-masked microparticles
• Direct-compression binders
• Effervescent or saliva-activated disintegration systems
• Low-moisture packaging and desiccant protection

The commercial opportunity is strongest where the product can provide discreet administration, pediatric acceptability, and controlled exposure without water.

Transdermal delivery

Daytrana uses a transdermal patch and creates a separate excipient opportunity. Relevant components include pressure-sensitive adhesives, penetration enhancers, backing layers, release liners, plasticizers, and crystallization-control agents.

Transdermal methylphenidate can provide flexible wear time and a period of declining exposure after patch removal. Technical barriers include skin irritation, adhesion across activity and perspiration, dose delivery variability, drug crystallization, and manufacturing uniformity.

What patents protect methylphenidate HCl formulations?

The active ingredient is off-patent in the United States. Current value is concentrated in formulation, delivery-system, manufacturing, and method-of-use patents.

Technology or product	Main protection type	Commercial relevance
Concerta and related OROS products	Osmotic tablet architecture, manufacturing, release profile	High formulation complexity; generic substitution has historically produced litigation
Ritalin LA	Biphasic multiparticulate release	Mature technology with generic competition
Quillivant XR	Extended-release liquid suspension and particle-release system	Stronger differentiation than immediate-release liquid
QuilliChew ER	Extended-release chewable matrix and taste-masking system	Pediatric and administration differentiation
Aptensio XR	Multiparticulate bead release	Capsule-based extended exposure
Jornay PM	Delayed-release and extended-release bead system	Chronotherapy and evening dosing
Cotempla XR-ODT	Extended-release orally disintegrating microparticles	Pediatric and water-free administration
Daytrana	Transdermal adhesive and delivery system	Manufacturing and device-related barriers

The core OROS patent family associated with Concerta included U.S. Patent No. 5,837,284, which expired in 2017, and later patents that addressed aspects of the extended-release system and manufacturing. Patent protection and FDA-listed patents have changed over time, so the current Orange Book entry must be assessed by product and patent family rather than by brand name alone (FDA, 2024a).

Methylphenidate formulation patents commonly claim:

1. Polymer-coated drug particles with defined dissolution profiles.
2. Immediate-release and delayed-release bead populations.
3. Osmotic tablets with specified membrane and core compositions.
4. Oral suspensions with controlled-release particles.
5. Chewable or orally disintegrating dosage forms.
6. Transdermal adhesive matrices.
7. Methods of treating ADHD with evening or flexible dosing.
8. Manufacturing parameters that affect release, coating thickness, or particle distribution.

When does methylphenidate HCl lose exclusivity?

Methylphenidate HCl itself has no meaningful U.S. compound-patent barrier. Exclusivity varies by product.

Product category	Typical protection profile
Immediate-release tablets	Generic competition; limited formulation exclusivity
Extended-release tablets	Formulation patents, regulatory exclusivity, and manufacturing know-how
Extended-release capsules	Bead coating and release-profile patents
Liquid suspension	Particle engineering, suspension stability, taste masking, and patent claims
Chewable tablets	Dosage-form and controlled-release matrix claims
ODT products	Disintegration, microparticle, and taste-masking claims
Transdermal patch	Device, adhesive, formulation, and manufacturing claims

FDA marketing exclusivity is distinct from patent protection. New dosage forms can receive three years of exclusivity for a qualifying new clinical investigation under section 505(b)(2), while pediatric exclusivity can add six months to relevant patent or exclusivity periods. Orphan-drug exclusivity is generally not relevant to standard ADHD products (FDA, 2024b).

What is the Orange Book status of methylphenidate products?

The Orange Book lists approved drug products, therapeutic equivalence evaluations, patents, and exclusivity information for eligible products. Immediate-release methylphenidate products generally have established generic pathways. The more commercially important questions concern specific extended-release brands and whether an ANDA applicant must certify against listed patents.

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed. For controlled-release methylphenidate products, Paragraph IV risk is concentrated in:

• Release-controlling polymer systems
• Particle-coating architecture
• Osmotic delivery components
• Delayed-release timing
• Tablet or capsule manufacturing processes
• Method-of-use claims covering dosing time or administration

A first substantially complete Paragraph IV filing may qualify for 180-day generic exclusivity if statutory requirements are met. The commercial value of that exclusivity depends on whether the reference product has meaningful remaining sales and whether other applicants can launch under different patent certifications.

Which companies compete in methylphenidate HCl formulations?

The competitive field includes originators, specialty pharmaceutical companies, generic manufacturers, and formulation-technology licensors.

Branded and specialty manufacturers

• Janssen and related Johnson & Johnson entities developed Concerta and historically marketed Ritalin-related products.
• Novartis has been associated with Ritalin and Ritalin LA.
• Tris Pharma markets or has marketed Quillivant XR, QuilliChew ER, and other methylphenidate formulations.
• Ironshore Pharmaceuticals developed Jornay PM.
• Rhodes Pharmaceuticals has marketed Aptensio XR.
• Neos Therapeutics developed Cotempla XR-ODT before its acquisition by Tris Pharma.
• Noven Pharmaceuticals developed Daytrana.

Generic manufacturers

Generic competition has involved companies such as Actavis, Teva, Mallinckrodt, Lannett, Prasco, and other ANDA sponsors, depending on the product and time period. Authorized generics can materially change price competition while preserving supply through a brand-linked manufacturing or licensing arrangement.

What licensing deals and technology partnerships affect methylphenidate?

The most commercially important licensing structures involve delivery technologies rather than methylphenidate HCl itself. Relevant deal categories include:

• OROS or osmotic delivery licenses
• Multiparticulate bead technology licenses
• Ion-exchange resin and polymer-coating licenses
• Orally disintegrating tablet platforms
• Transdermal patch and adhesive technology
• Controlled-substance manufacturing and distribution arrangements

A licensee evaluating methylphenidate should examine field-of-use restrictions, control of improvements, rights to pediatric indications, manufacturing-site obligations, technology-transfer requirements, and whether the licensed patents cover composition, process, or only a narrow release profile.

How strong is the methylphenidate HCl patent estate?

The estate is weak for the molecule and conventional immediate-release products but stronger for differentiated delivery systems.

Patent layer	Relative strength	Reason
Methylphenidate HCl composition	Low	Mature active ingredient
Immediate-release tablet excipients	Low	Easy substitution and extensive prior art
Osmotic extended-release tablet	Medium to high	Complex architecture and process dependence
Multiparticulate beads	Medium	Multiple design-around pathways
Delayed-release evening dosing	Medium to high	Narrow clinical and formulation combination
Liquid suspension	Medium	Particle engineering and stability claims can be valuable
Chewable and ODT platforms	Medium	Formulation differentiation is commercially clear
Transdermal patch	Medium to high	Device, adhesive, and manufacturing barriers
Manufacturing know-how	High operational value	Often difficult to reproduce even when patents expire

Patent strength depends on claim breadth, written-description support, enablement, prosecution history, prior-art density, and the ability to prove infringement through dissolution testing or manufacturing evidence.

What generic launch risks exist for methylphenidate HCl?

Generic launch risk is highest for immediate-release tablets and lowest for complex transdermal and chronotherapeutic products.

Primary risks include:

• Paragraph IV litigation over release-control patents
• FDA requests for additional comparative pharmacokinetic studies
• Failure to demonstrate bioequivalence under fed and fasting conditions
• Dose dumping after alcohol exposure
• Inconsistent suspension redispersion
• Bead-size and coating variability
• Controlled-substance quota limitations
• Manufacturing-site inspection findings
• Shortages of specialized coating polymers or functional excipients
• Competition from authorized generics
• State-level substitution and formulary restrictions

For a complex generic, the excipient system must be treated as part of the regulatory strategy. A nominally different excipient composition can create a meaningful design-around, but it may also alter bioequivalence, tolerability, stability, or release behavior.

What commercial opportunities exist for excipient suppliers?

The highest-value opportunities are functional systems rather than commodity excipients.

Taste-masking systems

Taste masking is relevant to liquid, chewable, and ODT products. Suppliers can offer coated methylphenidate particles, ion-exchange complexes, lipid barriers, and flavor systems with validated release after swallowing.

Pediatric excipient platforms

Pediatric products require low-volume dosing, flexible strengths, acceptable mouthfeel, and simple administration. A platform that supports liquid, sprinkle, chewable, and ODT formats can reduce development time across a product portfolio.

Controlled-release polymers

High-value polymers must provide predictable release at low drug loading, maintain performance across pH conditions, and tolerate scale-up. Ethylcellulose, hypromellose, acrylic copolymers, polyethylene oxide, and cellulose-based systems are relevant, but proprietary grade selection and process conditions create differentiation.

Abuse-deterrent formulation components

Methylphenidate is a controlled substance. Excipient systems that increase gel strength, resist crushing, limit solvent extraction, or reduce rapid release may support abuse-deterrent positioning. Such claims require clinical and human-abuse-liability evidence and cannot be inferred from mechanical resistance alone.

Transdermal materials

Pressure-sensitive adhesives, skin-tolerability modifiers, crystallization inhibitors, and permeation-control systems have value in patch products. Regulatory experience with adhesive extractables, residual solvents, and skin sensitization is a competitive advantage.

How does methylphenidate HCl compare with competing ADHD drugs?

Drug class	Excipient opportunity	Formulation barrier
Methylphenidate HCl	Liquid, chewable, ODT, osmotic, bead, patch	Mature API; complex delivery systems
Amphetamine mixed salts	ER beads, liquid, ODT	Strong branded formulation competition
Lisdexamfetamine	Prodrug capsule and chewable systems	Compound and product-specific protection historically stronger
Atomoxetine	Conventional oral and liquid products	Less complex release profile
Guanfacine ER	Hydrophilic matrix tablets	Matrix-release and method-of-use claims
Clonidine ER	Extended-release tablets	Release profile and dose management
Dexmethylphenidate HCl	ER capsules and tablets	Enantiomer-specific product positioning

Methylphenidate has an unusually broad dosage-form landscape. That diversity creates more excipient entry points than a conventional immediate-release CNS product, but it also creates product-specific bioequivalence and patent constraints.

Key Takeaways

• Methylphenidate HCl is off-patent as an active ingredient; commercial protection resides in delivery systems.
• Immediate-release tablets are low-margin and highly exposed to generic competition.
• The strongest excipient opportunities are in taste masking, extended-release polymers, multiparticulates, pediatric liquids, ODTs, chewables, and transdermal adhesives.
• Concerta-type osmotic systems have higher manufacturing complexity than conventional matrix tablets.
• Jornay PM creates an opportunity for delayed-release and evening-dosing technologies.
• Liquid and pediatric formulations require simultaneous control of palatability, suspension stability, dose uniformity, and release.
• Paragraph IV risk is product-specific and concentrates on formulation, process, and method-of-use patents.
• Controlled-substance quotas, manufacturing controls, and specialized coating processes can restrict generic entry even after key patents expire.
• Excipient suppliers with validated functional systems and regulatory support have greater commercial leverage than suppliers offering commodity grades alone.

FAQs

Can methylphenidate HCl be reformulated as a once-daily liquid?

Yes. An extended-release liquid requires controlled-release particles, suspension stability, dose uniformity, palatability, and demonstrated bioequivalence. Quillivant XR establishes regulatory and commercial precedent.

Which excipient is best for methylphenidate taste masking?

No single excipient is universally best. Ion-exchange resins, polymer-coated particles, lipid barriers, and multiparticulate encapsulation are the principal approaches. The choice depends on loading, release target, mouthfeel, and manufacturing process.

Does methylphenidate HCl qualify for a 505(b)(2) product?

A reformulated or new dosage-form product may qualify for a 505(b)(2) application when it relies partly on FDA findings for a listed drug and contains sufficient product-specific data. The pathway depends on the extent of formulation, pharmacokinetic, clinical, and safety differences.

Are methylphenidate HCl transdermal products interchangeable with oral products?

No. A transdermal patch has a different route of administration, absorption profile, application schedule, and safety profile. It is not therapeutically interchangeable with an oral methylphenidate product solely because both contain methylphenidate.

What is the main manufacturing barrier for extended-release methylphenidate?

The main barrier is reproducible control of release performance. Critical variables include particle-size distribution, coating thickness, polymer grade, tablet geometry, membrane integrity, moisture, and process scale-up.

References

1. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

2. U.S. Food and Drug Administration. (2024b). Code of Federal Regulations, Title 21, Part 314: Applications for FDA approval to market a new drug. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314

3. U.S. Food and Drug Administration. (2023a). Quillivant XR prescribing information. Tris Pharma.

4. U.S. Food and Drug Administration. (2023b). Jornay PM prescribing information. Ironshore Pharmaceuticals.

5. U.S. Food and Drug Administration. (2023c). Concerta prescribing information. Janssen Pharmaceuticals.

6. U.S. Food and Drug Administration. (2023d). Daytrana prescribing information. Noven Pharmaceuticals.

7. U.S. Patent No. 5,837,284. (1998). Controlled release tablet formulation.

8. U.S. Food and Drug Administration. (2024c). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/